Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …

Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …

For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …

Colorectal carcinoma (CRC) is a common cause of mortality, but a comprehensive
description of its genomic landscape is lacking,,,,,,–. Here we perform whole-genome …

Genome editing has therapeutic potential for treating genetic diseases and cancer.
However, the currently most practicable approaches rely on the generation of DNA double …

PD-1 blockade has transformed the management of advanced clear cell renal cell
carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely …

Chromosomal instability (CIN) results in the accumulation of large-scale losses, gains and
rearrangements of DNA. The broad genomic complexity caused by CIN is a hallmark of …

The altered metabolic programme of cancer cells facilitates their cell-autonomous
proliferation and survival. In normal cells, signal transduction pathways control core cellular …

Aneuploidies—whole-chromosome or whole-arm imbalances—are the most prevalent
alteration in cancer genomes,. However, it is still debated whether their prevalence is due to …

Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …